Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Inogen Inc    INGN

INOGEN INC

(INGN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Inogen : Short seller Carson Block targets medical device company Inogen

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/08/2019 | 11:16am EST
Carson Block, Chief Investment Officer, Muddy Waters Capital, speaks at the Sohn Investment Conference in New York

BOSTON (Reuters) - Prominent short seller Carson Block is saying that medical device company Inogen Inc has inflated the size of its markets and expects the stock price to fall.

Block, whose research firm Muddy Waters is best known for targeting the shares of China-based companies, has written a new report that asserts that Inogen's management has made overly optimistic growth forecasts.

The company's stock fell 6.2 percent Friday morning to $131.07. It had climbed steadily to as high as $282.92 in September.

Calls to the company's media relations and investor relations departments seeking comment were not returned.

Muddy Waters is short Inogen Inc because it question's Inogen's statements about total addressable market (TAM) size and potential growth, the report seen by Reuters said.

Inogen has a market capitalization of $3 billion and makes lightweight portable oxygen concentrators that free its users from being tethered to heavy tanks.

While the company has said the U.S. TAM is roughly 3 million users and is growing at 7 percent to 10 percent a year, Block said the real U.S. TAM is far smaller at about 1.3 million, citing Centers for Medicare & Medicaid Services (CMS) data. He also said CMS data shows that the oxygen therapy market has been shrinking. He wrote that Inogen based its estimates on data from Wintergreen Research.

"The key to INGN's extreme multiple is its blue sky story," the report said.

Block sees more room for it to fall, arguing that "INGN will hit peak sales as soon as this year, and likely no later than next." Block wrote in the report "At our forecast of peak earnings, we value INGN at $46 per share, a 67 percent decrease

from its current price."

Block ranks among the industry's most closely followed short-sellers, who seek to make money when a stock price falls. Some occasionally publish research reports detailing what they consider to be wrong with a company.

Dedicated short-sellers like Block, whose fund oversees roughly $210 million, tend to manage small amounts of money and often face uphill battles when the stock market is zooming higher.

Last year when Block published three reports, including one on Chinese tutoring company TAL Education Group, his fund earned 20 percent after fees. The Standard & Poor's 500 index fell 4.4 percent and the activist investors on average lost 11.25 percent.

Block, who trained as a lawyer but started his career as an equity analyst, distributed his research for free for years and said it took him years to create his hedge fund, which was launched in 2016.

(Reporting by Svea Herbst-Bayliss; Editing by Steve Orlofsky)

By Svea Herbst-Bayliss

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INOGEN INC
02/12INOGEN : Announces Participation in the 8th Annual Leerink Partners Global Healt..
BU
02/12INOGEN : Former California Deputy Attorney General and Special Counsel with John..
PR
02/08INOGEN : Short seller Carson Block targets medical device company Inogen
RE
02/05INOGEN : to Announce Fourth Quarter and Full Year 2018 Financial Results on Tues..
BU
01/07INOGEN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8..
AQ
01/02INOGEN : Announces Participation in the 2019 J.P. Morgan Healthcare Conference
BU
01/02INOGEN : Announces Participation in the 21st Annual Needham Growth Conference
BU
2018INOGEN : Announces Launch of Inogen Connect
BU
2018INOGEN : Announces Participation in Nasdaq's 39th London Investor Conference
BU
2018INOGEN : Announces Participation in the Piper Jaffray 30th Annual Healthcare Con..
BU
More news
Financials ($)
Sales 2018 354 M
EBIT 2018 39,0 M
Net income 2018 47,7 M
Finance 2018 186 M
Yield 2018 -
P/E ratio 2018 67,03
P/E ratio 2019 65,29
EV / Sales 2018 8,11x
EV / Sales 2019 6,42x
Capitalization 3 054 M
Chart INOGEN INC
Duration : Period :
Inogen Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOGEN INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 231 $
Spread / Average Target 63%
EPS Revisions
Managers
NameTitle
Scott Wilkinson President, Chief Executive Officer & Director
Heath Lukatch Chairman
Bart Sanford Executive Vice President-Operations
Alison K. Bauerlein CFO, Secretary, Treasurer & Executive VP
Brenton Taylor Executive Vice President-Engineering
Sector and Competitors
1st jan.Capitalization (M$)
INOGEN INC14.27%3 054
MEDTRONIC PLC0.30%123 923
BAXTER INTERNATIONAL10.06%39 075
ZIMMER BIOMET HOLDINGS19.22%25 222
HOYA CORPORATION3.55%23 083
TERUMO CORP8.16%22 589